COVID-19 vaccines safe for patients treated for lung cancer with immune checkpoint inhibitors

Patients with cancer are at an increased risk for SARS-CoV-2 infection and severe COVID-19 because of the lowered immunity associated with anticancer drugs, radiation therapy, and cancer itself, as well as increased exposure due to frequent visits to the hospital.

Related Keywords

Japan ,Denver ,Colorado ,United States ,Japanese ,Makoto Hibino ,Shonan Fujisawa Tokushukai ,Chris Martin , ,Thoracic Oncology ,International Association ,Shonan Fujisawa Tokushukai Hospital ,Association ,Cancer ,Immune System ,Infection ,Lung Cancer ,Medicine ,Oncology ,Radiation Therapy ,Vaccination ,Cancer Immunotherapy ,Checkpoint Inhibitor ,Clinical Medicine ,Health Effects Of Tobacco ,Treatment Of Lung Cancer ,